Tasigna Articles

FDA approves Teva's Synribo for CML; Novartis plans for Tasigna switch

29 October 2012

UK NICE issues final guidance for Tasigna, Glivec, Sprycel, Victrelis and Incivo

25 April 2012

"NICE" news for Novartis CML drugs, but not for Bristol-Myers

22 March 2012

Mixed NICE recommendations for CML and diabetes drugs

13 January 2012

More news for ASH meeting

13 December 2011

UK NICE recommends Novartis drugs for chronic myeloid leukemia, but not Bristol-Myers’ Sprycel

6 December 2011

UK’s NICE asks for more info on Boehringer’s Pradaxa; backs Novartis’ Tasigna but not Glivec or B-MS Sprycel for leukemia

18 August 2011

UK’s NICE says “no” to Novartis Tasigna and B-MS Sprycel, but better news on Afinitor

6 May 2011

Novartis drops Ph III Tasigna trial for GIST; in-licenses Sativex; and reports new Gilenya data

11 April 2011

Novartis gains EU approval for Tasigna in new Ph+ CML patients; files Bexsero MAA

24 December 2010

Novartis’ Tasigna approved in Japan; JAK inhibitor INC424 meets primary Ph III endpoint

22 December 2010

ASH meeting: Pfizer’s bosutinib disappoints in myeloid leukemia trial; Novartis’ Tasigna beats Glivec in CML study

7 December 2010

Regulatory briefs: Shire’s Vpriv cleared in Europe; Menactra for toddlers; Updates for Novartis and Roche

27 August 2010

Novartis gets US FDA approval for new Tasigna indication; agency panel backs HRA Pharma's ulipristal

18 June 2010

Novartis’ Afinitor meets primary endpoint in Ph III study of patients with advanced NET; Tasigna shows benefits over Glivec/Gleevec

4 June 2010

Showing 1-15 of 15 articles

Go to beginningPrevious
  • 1
NextGo to end